- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02790918
Diagnosis of Pulmonary Hypertension Using Cardiac Magnetic Resonance Images
Noninvasive Diagnosis of Pulmonary Hypertension Using Three-dimensional Interventricular Septal Curvedness From Cardiac Magnetic Resonance Images
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
1) Pulmonary hypertension Pulmonary hypertension (PH) is manifested as an increase in mean pulmonary artery pressure (i.e., mPAP ≥ 25 mmHg) at rest on right heart catheterization (RHC) (Badesch 2009). It is a complex and multidisciplinary disorder causing restricted flow through the pulmonary arterial circulation due to increased pulmonary vascular resistance (PVR). It can be classified into five groups (Simonneau et al 2004): Group I - Idiopathic PAH, Familial PAH, and PAH associated with collagen vascular disease et al; Group II - PH with left heart disease; Group III - PH associated with lung diseases and/or hypoxemia; Group IV - PH due to chronic thrombotic and/or embolic disease; and Group V - miscellaneous causes of PH. The prognosis of PH is poor. The National Institutes of Health (NIH) Registry followed 194 patients with IPAH enrolled at 32 clinical centers from 1981 to 1985 (D'Alonzo et al 1991). The reported median survival rates of 68%, 48% and 34%. Similar results have been reported in Japan, India and Mexico.
Right heart catheterization (RHC) is the current reference standard for diagnosing PH (Galie et al 2009; McLaughlin et al 2009), according to ACCF/AHA expert consensus (McLaughlin et al 2009) and ESC/ERS guidelines (Galie et al 2009). Three hemodynamic measurements are essential from RHC: right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). Further, patients with PH undergo RHC to assess clinical response to vasodilator challenge in order to guide therapy. It helps identify patients with better prognosis and patients who could potentially benefit from treatment with calcium channel blockers. A positive acute response is defined as a reduction of pulmonary artery pressure ≥10mmHg and ≤40mmHg. Although RHC plays a pivotal role in PH diagnosis, it is invasive and not without its own inherent risks (Hoeper et al 2006). For these reasons, development of a noninvasive alternative to RHC for diagnosis of PH is paramount.
Noninvasive diagnosis of PH and prediction of response to vasodilator challenge is clinically needed.
Several noninvasive methods for diagnosis of PH have been propounded, the most common being Doppler echocardiography. While routinely used to estimate pulmonary arterial pressure, Doppler measurement of tricuspid regurgitation jet peak velocity has inherent limitations: (i) the reliance on the visualization of the tricuspid regurgitant jet which is not always detectable, (ii) the fact that peak velocity of the jet may be difficult to measure in the presence of severe tricuspid regurgitation, and (iii) the need for adequate acoustic windows (Hinderliter et al 2003; Hachulla et al 2005). Furthermore, as recently emphasized in the ERS/ESC guideline (Galie et al 2009), estimation of mPAP or PVR must be an integral part of a complete cardiac echocardiographic examination.
It has long been recognized that systolic flattening and abnormal motion of the inter-ventricular septum (IVS), from either echocardiography (King et al 1983; Reisner et al 1994; Ricciardi et al 1999) or cine CMR images (Roeleveld et al 2005; Dellegrottaglie et al 2007; Alunni et al 2010), are signs of increased pulmonary arterial pressures. However, these studies are either qualitative or limited to 2D assessment, relying for analysis on subjective selection of the imaging plane and cardiac cycle phase. In the last 10 years, despite advances in biomedical engineering and computational approaches, no rigorous studies have been undertaken to study the relationship between quantitative 3D IVS shape and PH.
It is well documented that RV dysfunction and the 6-min walk test (6MWT) are associated with increased risk of mortality in PH (van Wolfersen 2007). Study team has recently developed a new method for assessment of RV function in terms of area strain, integrating radial, circumferential and longitudinal deformation (Zhong et al 2012). Therefore, we will also investigate the relationship between RV area strain and exercise capacity in PH.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 169609
- National Heart Centre Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
30 diagnosed pulmonary hypertension patient will be recruited from primary care clinic and outpatient clinics from the National Heart Centre Singapore.
30 Healthy volunteer control.
Description
Inclusion Criteria:
- Signed informed consent prior to initiation of any study mandated procedure
- Age 16 years or more.
- Patient with clinically suspected or known primary PH belonging to one of the Updated Dana Point Clinical Classification Groups (I-IV)
- No known history of pulmonary hypertension
Exclusion Criteria:
Contraindication to MR examination:
- Cardiac pacemaker
- Brain aneurysm or clips
- Electronic implants or prosthesis
- Eye metal foreign body injury
- Severe claustrophobia
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Diagnosed Pulmonary Hypertension
Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
|
Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory.
Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour.
Several sets of images are needed.
No injection of drug or dye will be used for this procedure.
|
|
Healthy Volunteer
Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
|
Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory.
Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour.
Several sets of images are needed.
No injection of drug or dye will be used for this procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
First occurrence of cardiovascular event.
Time Frame: 1-Year
|
1-Year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Liang Zhong, PhD, National Heart Centre Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/290/C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
Clinical Trials on 6MWT
-
David ToupinNot yet recruitingNeuromuscular Diseases in ChildrenUnited States
-
Schön Klinik Berchtesgadener LandROX Medical, Inc.CompletedChronic Obstructive Pulmonary DiseaseGermany
-
Oxford University Hospitals NHS TrustMalmö UniversityCompleted
-
Oxford University Hospitals NHS TrustUniversity of OxfordCompletedPulmonary HypertensionUnited Kingdom
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseNetherlands, Ireland, France, Italy, Canada, Russian Federation
-
Colorado Prevention CenterCompletedPeripheral Artery DiseaseUnited States
-
University of ZurichCompletedHigh Altitude Pulmonary HypertensionKyrgyzstan
-
University of ZurichCompletedHigh Altitude Pulmonary HypertensionKyrgyzstan
-
Jessa HospitalRecruitingAortic Valve StenosisBelgium